Otros idiomas Monte Rosa Therapeutics, Inc.

Acciones

GLUE

US61225M1027

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 15/05/2024			Pre-apertura 13:31:49
5,23 ^USD	+4,60 %		4,785	-8,51 %

09/05	Monte Rosa Therapeutics, Inc. Resultados del primer trimestre finalizado el 31 de marzo de 2024	CI
02/05	Monte Rosa Therapeutics, Inc. Anuncia la salida de Owen Wallace como Director Científico y la transición a miembro de su Consejo Científico Asesor	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering	13:01
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants	15/05
Monte Rosa Therapeutics : Corporate Presentation - May 2024	09/05
Monte Rosa Therapeutics: Q1 Earnings Snapshot	09/05
Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update	09/05
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer	02/05
Monte Rosa Therapeutics, Inc. Announces Departure of Owen Wallace as Chief Scientific Officer and Transition to Member of its Scientific Advisory Board	02/05
Monte Rosa Therapeutics : AACR 2024 – The GSPT1 Molecular Glue Degrader MRT-2359 Is Active against Prostate Cancer	03/04
Monte Rosa Therapeutics Q4 Net Loss Narrows; Shares Decline	14/03
Monte Rosa Therapeutics: Q4 Earnings Snapshot	14/03
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	14/03
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/03
Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor	11/03
Monte Rosa Therapeutics, Inc. Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1b Pathway Inhibitor	11/03
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences	31/01
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024	08/01
Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference	03/01
Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from NASDAQ Biotechnology Index	15/12
Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference	21/11

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Monte Rosa Therapeutics, Inc.

Acciones

GLUE

US61225M1027

Otros idiomas

Filtros